Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement
1. Citius Oncology announced a direct offering of 5,142,858 shares. 2. The offering includes warrants exercisable after six months. 3. Expected gross proceeds are approximately $9 million. 4. Citius’s primary drug, LYMPHIR, targets a $400 million market. 5. Management expects LYMPHIR to significantly impact oncology market.